Philogen
Developing targeted biopharmaceuticals for oncology using proprietary ligand-based delivery.
PHIL | XMIL
Overview
Corporate Details
- ISIN(s):
- IT0005373789 (+1 more)
- LEI:
- 81560009EA1577917768
- Country:
- Italy
- Address:
- PIAZZA LA LIZZA, 7, 53100 SIENA
- Website:
- https://www.philogen.com
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Philogen is a Swiss-Italian biotechnology company, founded in 1996, that develops innovative biopharmaceuticals for the treatment of cancer and other serious conditions. The company is a pioneer in proprietary ligand-based targeting approaches, which use high-affinity antibodies and small molecules to deliver therapeutic agents directly to the site of disease. As a fully-integrated company, its expertise spans from the discovery of novel tumor markers using chemical proteomics to the GMP manufacturing of its targeted therapies, such as immunocytokines and radioligand therapeutics. Philogen's clinical-stage pipeline focuses primarily on oncology indications.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-10-06 18:50 |
Director's Dealing
Allegato 3F
|
Italian | 26.9 KB | ||
| 2025-10-06 18:15 |
Transaction in Own Shares
2025 10 06 - CS settimanale acquisto azioni proprie
|
Italian | 294.0 KB | ||
| 2025-09-29 17:58 |
Transaction in Own Shares
2025 09 29 - CS settimanale acquisto azioni proprie
|
Italian | 298.0 KB | ||
| 2025-09-26 12:26 |
Interim Report
Half Year Report 2025 as of 30.06.2025 (Courtesy English Translation)
|
English | 2.1 MB | ||
| 2025-09-26 12:24 |
Interim Report
Relazione Finanziaria Semestrale al 30.06.2025
|
Italian | 2.0 MB | ||
| 2025-09-23 21:11 |
Earnings Release
The Board of Directors Approves the Half-Yearly Financial Report at 30 June 202…
|
English | 416.6 KB | ||
| 2025-09-23 21:10 |
Interim Report
Il Consiglio di Amministrazione Approva la Relazione Finanziaria Semestrale al …
|
Italian | 377.0 KB | ||
| 2025-09-15 14:52 |
Transaction in Own Shares
2025 09 15 - CS settimanale acquisto azioni proprie
|
Italian | 184.3 KB | ||
| 2025-08-18 20:02 |
M&A Activity
Press Release Clearance e Closing OncoACP3 (Price Sensitive)
|
Italian | 213.9 KB | ||
| 2025-07-07 16:50 |
Transaction in Own Shares
2025 07 07 - CS settimanale acquisto azioni proprie
|
Italian | 153.0 KB | ||
| 2025-07-07 12:08 |
Director's Dealing
Allegato 3F
|
Italian | 26.7 KB | ||
| 2025-06-30 17:04 |
Transaction in Own Shares
2025 06 30 - CS settimanale acquisto azioni proprie
|
Italian | 181.7 KB | ||
| 2025-06-25 12:29 |
Legal Proceedings Report
Philogen Provides Update on Marketing Authorization Application for Nidlegy™ in…
|
English | 180.5 KB | ||
| 2025-06-11 01:34 |
Regulatory News Service
Press Release Licenza OncoACP3 (Price Sensitive)
|
Italian | 225.0 KB | ||
| 2025-06-03 13:40 |
Transaction in Own Shares
2025 06 03 - CS settimanale acquisto azioni proprie
|
Italian | 144.1 KB |
Automate Your Workflow. Get a real-time feed of all Philogen filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for Philogen via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
/other/Diamyd_Medical_AB_publ-logo.png){kind=logo}
